- Home
- JD vs IQV Comparison
JD vs IQV Comparison
Compare JD & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JD | IQV |
|---|---|---|
| Founded | 2006 | 1982 |
| Country | China | United States |
| Employees | 900000 | 93000 |
| Industry | Other Specialty Stores | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.9B | 35.1B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | JD | IQV |
|---|---|---|
| Price | $32.91 | $235.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 16 |
| Target Price | $39.27 | ★ $227.13 |
| AVG Volume (30 Days) | ★ 7.3M | 1.3M |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.37% | N/A |
| EPS Growth | N/A | ★ 4.67 |
| EPS | N/A | ★ 1.61 |
| Revenue | N/A | ★ $9,739,000,000.00 |
| Revenue This Year | $8.17 | $6.77 |
| Revenue Next Year | $6.01 | $5.89 |
| P/E Ratio | ★ $9.17 | $148.13 |
| Revenue Growth | N/A | ★ 41.60 |
| 52 Week Low | $24.51 | $154.50 |
| 52 Week High | $36.86 | $251.36 |
Technical Indicators
Market Signals| Indicator | JD | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 78.19 | 65.89 |
| Support Level | $32.17 | $218.57 |
| Resistance Level | $34.30 | $245.60 |
| Average True Range (ATR) | 0.53 | 7.29 |
| MACD | 0.37 | 2.68 |
| Stochastic Oscillator | 98.52 | 65.27 |
Price Performance
Historical ComparisonAbout JD JD.com Inc.
JD.com is the third-largest Chinese e-commerce platform by gross merchandise volume in 2025. It offers a wide selection of authentic products with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace, and omnichannel businesses.
About IQV IQVIA Holdings Inc.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.